Banque Cantonale Vaudoise cut its stake in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 38.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,276 shares of the medical instruments supplier’s stock after selling 2,651 shares during the period. Banque Cantonale Vaudoise’s holdings in Insulet were worth $682,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Amalgamated Bank raised its stake in Insulet by 3.5% during the 3rd quarter. Amalgamated Bank now owns 18,818 shares of the medical instruments supplier’s stock valued at $3,001,000 after buying an additional 634 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Insulet in the 3rd quarter worth $389,000. New York Life Investment Management LLC increased its stake in shares of Insulet by 0.8% in the 3rd quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock worth $1,600,000 after purchasing an additional 82 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Insulet by 1.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 22,552 shares of the medical instruments supplier’s stock worth $3,597,000 after purchasing an additional 323 shares in the last quarter. Finally, Qsemble Capital Management LP purchased a new stake in shares of Insulet in the 3rd quarter worth $298,000.
Insulet Stock Performance
Insulet stock opened at $199.63 on Wednesday. The firm has a market capitalization of $13.94 billion, a P/E ratio of 116.74, a price-to-earnings-growth ratio of 2.14 and a beta of 1.05. The company’s 50-day moving average is $202.51 and its 200 day moving average is $189.79. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91. The company has a debt-to-equity ratio of 2.26, a current ratio of 3.26 and a quick ratio of 2.35.
Insider Transactions at Insulet
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. reduced their price objective on Insulet from $325.00 to $162.00 and set an “overweight” rating for the company in a research note on Tuesday, October 17th. Stifel Nicolaus increased their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday. Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $180.00 to $238.00 in a research note on Thursday, December 21st. Leerink Partnrs reissued an “outperform” rating on shares of Insulet in a report on Monday, October 16th. Finally, SVB Leerink initiated coverage on shares of Insulet in a report on Monday, October 16th. They set an “outperform” rating and a $184.00 price objective for the company. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average price target of $250.40.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Five stocks we like better than Insulet
- Canada Bond Market Holiday: How to Invest and Trade
- Exxon and Chevron ready to rally: The floor is in for big oil
- How to Use the MarketBeat Stock Screener
- Analysts jumped on this stock ahead of earnings; markets love it
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Unusual call options in this ETF can lead these stocks to rally
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.